Jonathan S. Dordick | |
---|---|
Born | Philadelphia, Pennsylvania | January 15, 1959
Education | MIT Brandeis University |
Known for | Methods for rapidly screening drug efficacy and toxicity |
Awards | Marvin J. Johnson Award,American Chemical Society; Elmer Gaden Award, American Chemical Society; Iowa Section Award, American Chemical Society |
Scientific career | |
Fields | Bioengineering Biocatalysis Biomolecular Interaction Metabolomics Cell-based Microarrays Nanobiotechnology Magnetogenetics |
Institutions | Rensselaer Polytechnic Institute |
Academic advisors | D.I.C. Wang Alexander Klibanov |
Jonathan S. Dordick (born January 15, 1959) is an institute professor of chemical and biological engineering at Rensselaer Polytechnic Institute and holds joint appointments in the departments of biomedical engineering and biological sciences. In 2008 he became director of the Center for Biotechnology and Interdisciplinary Studies. In 2012 Dordick became the vice president for research at RPI. [1] He became Special Advisor to the RPI President for Strategic Initiatives in 2018,
Dordick was elected a member of the National Academy of Engineering in 2021 for contributions to methods for rapidly screening drug efficacy and toxicity, and biocatalytic technologies for improving human health.
Dordick received his B.A. degree in biochemistry and chemistry from Brandeis University and his Ph.D. from the Massachusetts Institute of Technology in biochemical engineering. In 1987, Dordick joined the department of chemical and biochemical engineering at the University of Iowa. He was promoted to associate professor in 1991, to full professor in 1994, and served as department chair from 1995 to 1998. In 1998, Dordick joined the faculty at Rensselaer Polytechnic Institute as chair of the department of chemical and biological engineering and the Howard P. Isermann Professor. He served as director of the Center for Biotechnology and Interdisciplinary Studies from 2008-2012 and as vice president for research at RPI from 2012 to 2018. Since 2018, Dordick has been the co-director of the Heparin Applied Research Center and the senior advisor to the Rensselaer president for strategic initiatives. Dordick is a member of the National Academy of Engineering and the National Academy of Inventors. He is a Fellow of the American Chemical Society, the American Association for the Advancement of Science, and the American Institute of Medical and Biological Engineers. He has received numerous awards, including the Amgen Award in Biochemical and Molecular Engineering, Food, Pharmaceutical and Bioengineering Award of the American Institute of Chemical Engineers, Marvin J. Johnson Award and the Elmer Gaden Award both of the American Chemical Society, the International Enzyme Engineering Award, and an NSF Presidential Young Investigator Award. He has cofounded several companies, including EnzyMed (now part of Albany Molecular Research, Inc.), Solidus Biosciences, Inc., and Redpin Therapeutics. He has also served on multiple White House-sponsored panels and committees in biomanufacturing. Dordick has published over 400 papers and is an inventor/co-inventor on nearly 50 patents and patent applications.
He is married to Vera. Dordick has a son, Samuel, and a daughter, Hannah.
Professor Dordick currently leads the Jonathan S. Dordick Research Group in the Center for Biotechnology and Interdisciplinary Studies and leads research in enzyme technology, microscale cell culture engineering, drug discovery and human toxicology, and biomanufacturing. [2] Present and past research has included studies of Biocatalysis in Nonaqueous Media, Combinatorial Biocatalysis, Nanobiotechnology, enzyme technology, molecular bioprocessing. More specifically, they work on the development of enzymatic catalysis under extreme conditions (e.g. high salt concentrations), enzymes in the synthesis and modification of polymeric materials, combinatorial biocatalysis for drug discovery and polymer synthesis, and the generation of biocatalysts and biomimetics with unique activities and selectivities. [2] Dordick has been featured in the news for helping develop the "MetaChip" technology for fast drug screening, and for research on gel nanomaterials that could be used to control the delivery of drugs. [3] [4] Most recently, Dordick has tackled COVID-19 by identifying mechanisms that interfere with SARS-CoV-2 entry into human cells. He identified the ability of heparin, a common blood thinner, to block the virus' ability to bind to its human receptor target. [5] He then identified other highly sulfated polysaccharides, including those from seaweed, [6] which also possessed very potent activity against viral infectivity in vitro.
Rensselaer Polytechnic Institute is a private research university in Troy, New York. It is the oldest technological university in the English-speaking world and the Western Hemisphere. It was established in 1824 by Stephen Van Rensselaer and Amos Eaton for the "application of science to the common purposes of life".
Biochemical engineering, also known as bioprocess engineering, is a field of study with roots stemming from chemical engineering and biological engineering. It mainly deals with the design, construction, and advancement of unit processes that involve biological organisms or organic molecules and has various applications in areas of interest such as biofuels, food, pharmaceuticals, biotechnology, and water treatment processes. The role of a biochemical engineer is to take findings developed by biologists and chemists in a laboratory and translate that to a large-scale manufacturing process.
Peter G. Schultz is an American chemist, entrepreneur, and nonprofit leader. He is the CEO and President and Professor of Chemistry at Scripps Research, the founder and former director of GNF, and the founding director of the California-Skaggs Institute for Innovative Medicines, established in 2012. In August 2014, Nature Biotechnology ranked Schultz the #1 top translational researcher in 2013. Schultz's contributions to the field of chemistry have included the development and application of methods to expand the genetic code of living organisms, the discovery of catalytic antibodies, and the development and application of molecular diversity technologies to address problems in chemistry, biology, and medicine.
Rahul Sarpeshkar is the Thomas E. Kurtz Professor and a professor of engineering, professor of physics, professor of microbiology & immunology, and professor of molecular and systems biology at Dartmouth. Sarpeshkar, whose interdisciplinary work is in bioengineering, electrical engineering, quantum physics, and biophysics, is the inaugural chair of the William H. Neukom cluster of computational science, which focuses on analog, quantum, and biological computation. The clusters, designed by faculty from across the institution to address major global challenges, are part of President Philip Hanlon's vision for strengthening academic excellence at Dartmouth. Prior to Dartmouth, Sarpeshkar was a tenured professor at the Massachusetts Institute of Technology and led the Analog Circuits and Biological Systems Group. He is now also a visiting scientist at MIT's Research Laboratory of Electronics.
Jay D. Keasling is a professor of chemical engineering and bioengineering at the University of California, Berkeley. He is also associate laboratory director for biosciences at the Lawrence Berkeley National Laboratory and chief executive officer of the Joint BioEnergy Institute. He is considered one of the foremost authorities in synthetic biology, especially in the field of metabolic engineering.
Biological engineering or bioengineering is the application of principles of biology and the tools of engineering to create usable, tangible, economically viable products. Biological engineering employs knowledge and expertise from a number of pure and applied sciences, such as mass and heat transfer, kinetics, biocatalysts, biomechanics, bioinformatics, separation and purification processes, bioreactor design, surface science, fluid mechanics, thermodynamics, and polymer science. It is used in the design of medical devices, diagnostic equipment, biocompatible materials, renewable energy, ecological engineering, agricultural engineering, process engineering and catalysis, and other areas that improve the living standards of societies.
The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies is a research facility at Rensselaer Polytechnic Institute (RPI). The 218,000-square-foot (20,300 m2) building is located on 15th Street between RPI’s Playhouse and Academy Hall, next to the Center for Industrial Innovation. The institute hopes the new facility will help to encourage collaboration between experts in different fields, allowing them to solve problems that they would be unable to solve alone. The current director of the center is Juergen Hahn, succeeding Deepak Vashishth, Jonathan Dordick, and Robert Palazzo. The building cost $100M.
The Manchester Institute of Biotechnology, formerly the Manchester Interdisciplinary Biocentre (MIB) is a research institute of the University of Manchester, England.
Daniel I-Chyau Wang was a Chinese-American chemical engineer. He was an Institute Professor at the Massachusetts Institute of Technology. He was known for founding the MIT Biotechnology Process Engineering Center and the expansion of the field of biochemical engineering.
Robert J. Linhardt is the Ann and John Broadbent, Jr. '59 Senior Constellation Professor Biocatalysis & Metabolic Engineering at Rensselaer Polytechnic Institute.
Wei-Shou Hu is a Taiwanese-American chemical engineer. He is currently the Distinguished McKnight University Professor of Chemical Engineering and Material Science at the University of Minnesota.
Alan J. Russell, is Vice President of Biologics for Amgen, one of the world’s leading Biopharmaceutical companies. Until 2020, Alan was the Highmark Distinguished Career Professor and Director of the Disruptive Health Technology Institute at Carnegie Mellon University. From 2013 through spring of 2016 he was also the Chief Innovation Officer, Allegheny Health Network.
Nigel Shaun Scrutton is a British biochemist and biotechnology innovator known for his work on enzyme catalysis, biophysics and synthetic biology. He is Director of the UK Future Biomanufacturing Research Hub, Director of the Fine and Speciality Chemicals Synthetic Biology Research Centre (SYNBIOCHEM), and Co-founder, Director and Chief Scientific Officer of the 'fuels-from-biology' company C3 Biotechnologies Ltd. He is Professor of Enzymology and Biophysical Chemistry in the Department of Chemistry at the University of Manchester. He is former Director of the Manchester Institute of Biotechnology (MIB).
Greg N. Stephanopoulos is an American chemical engineer and the Willard Henry Dow Professor in the department of chemical engineering at the Massachusetts Institute of Technology. He has worked at MIT, Caltech, and the University of Minnesota in the areas of biotechnology, bioinformatics, and metabolic engineering especially in the areas of bioprocessing for biochemical and biofuel production. Stephanopoulos is the author of over 400 scientific publications with more than 35,000 citations as of April 2018. In addition, Greg has supervised more than 70 graduate students and 50 post-docs whose research has led to more than 50 patents. He was elected a fellow of the American Association for the Advancement of Science (2005), a member of the National Academy of Engineering (2003), and received the ENI Prize on Renewable Energy 2011.
Pierre Monsan is a French biochemist and entrepreneur. He is currently Professor emeritus at the Institut national des sciences appliquées de Toulouse and the founding director of the pre-industrial demonstrator Toulouse White Biotechnology (TWB).
Marco Wilhelmus Fraaije is a Dutch scientist whose research concerns enzymology of redox enzymes, enzyme discovery & engineering and biocatalysis at the Groningen Biomolecular Sciences and Biotechnology Institute (GBB) at the University of Groningen.
Jerome Schultz is an American bioengineering researcher, professor, and university administrator. He is a fellow of several national scientific societies and a member of the National Academy of Engineering. He has held professorships at the University of Michigan, the University of Pittsburgh, University of California, Riverside, and he is currently a Distinguished Professor of Biomedical Engineering at the University of Houston.
David W. Wood is an American chemical engineer who is professor of chemical and biomolecular engineering at Ohio State University. Wood is also associated with the Department of Chemistry and Biochemistry and Molecular Biophysics Training Program.
Blake A. Simmons is an American chemical engineer, entrepreneur and an academic. He is an adjunct professor at the University of Queensland, and the University of Hawaiʻi at Hilo, the division director for biological systems and engineering at Lawrence Berkeley National Laboratory, and the chief science and technology officer at the Joint BioEnergy Institute.